Insulin analogs

Human insulin has two chains totaling 51 amino acids. Analog changes—selected amino-acid substitutions or an added fatty-acid chain—alter absorption and duration while preserving the core insulin-receptor action. This is a class-level reference covering selected named products, not one molecule.

Supporting references: discontinued.

Insulin treatment began in the early 1920s and changed diabetes from a fatal disease into a manageable condition. Animal-derived and later recombinant human insulin did not precisely mimic physiological secretion: regular insulin was relatively slow at meals, while intermediate preparations produced overnight peaks and troughs. Lispro, first approved in 1996, and glargine, approved in 2000, introduced faster meal coverage and flatter basal exposure.

Insulin analogs act through the insulin receptor in muscle, adipose tissue and liver. Signaling promotes cellular glucose uptake through GLUT4, supports storage of glucose, fat and protein, and suppresses hepatic glucose production. The chemical modifications primarily change timing rather than the fundamental glucose-lowering mechanism.

Rapid analogs dissociate and absorb quickly to match meals. Basal products are designed to precipitate or bind albumin for slower release and background coverage. In Treat-to-Target, adding a basal analog to oral therapy enabled more participants to reach their HbA1c goal without documented nocturnal hypoglycemia than older NPH insulin.

Supporting references: goal.

FDA-approved analogs date from lispro in 1996 and include glargine, aspart, glulisine, detemir and degludec, with adult and, for many specific products, pediatric diabetes indications. Insulin is essential in type 1 diabetes and may be added in type 2 when other therapy is insufficient. Regimens can combine basal and mealtime products and use a pen, syringe or pump. The correct regimen belongs to the specific product and patient rather than a generic class dose.

Supporting references: FDA-approved.

Hypoglycemia is the most important common adverse effect and may progress to seizures or loss of consciousness. Weight gain, injection-site reactions, lipodystrophy and hypokalemia are other concerns. Combined use with thiazolidinediones can contribute to fluid retention and heart failure. An insulin pen must never be shared, even after changing its needle.